Aspect is building a factory to produce artificially grown cells that can be implanted to treat patients with damaged organs like pancreases and livers. The $49-million federal contribution is from its Strategic Innovation Fund; the provincial government is contributing $23.75 million. Together they’re supporting a $200-million project that includes the factory, advancing Aspect’s technology platform and finding new medical uses for it. (The Logic)

Talking point: Aspect’s product pipeline includes potential treatments for diabetes and liver failure, though both streams are still pre-clinical, meaning they haven’t been tried in live patients yet. Danish pharma giant Novo Nordisk—a major producer of insulin and, famously, Ozempic for obesity—has partnered with Aspect on its pancreas research in a deal that could be worth nearly US$2.7 billion plus royalties if multiple treatments make it to market.